Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments, Corp. reported an insider equity event involving executive Conrad Wai. On April 15, 2026, 23,463 shares of Class A Common Stock were automatically withheld at $2.04 per share to cover tax obligations arising from the vesting of restricted stock units granted in October 2024.
The vested portion represented 6.25% of the original RSU grant, with additional 6.25% installments scheduled to vest quarterly through October 15, 2028, subject to continued service. Following this tax-withholding disposition, Wai holds 1,169,914 shares directly and 1,610,482 shares indirectly through a family trust where he is co-trustee.
Clover Health Investments, Corp. executive Joseph Frank Oldakowski, Vice President of Finance and Controller, filed an initial ownership report. He beneficially owns 311,169 shares of Class A common stock underlying unvested time-based restricted stock units as of March 30, 2026. These restricted stock units were originally granted on June 16, 2025 and December 19, 2025, reflecting equity-based compensation rather than recent open-market trading.
Clover Health Investments (CLOV) interim CFO Joseph Clay Thornton reported his equity holdings in an amended Form 3. He beneficially owns 1,238,684 shares of Class A common stock directly. This total includes 912,860 shares underlying the remaining unvested portion of time-based restricted stock unit awards as of March 30, 2026, originally granted on February 16, 2024, October 15, 2024 and December 19, 2025.
Clover Health Investments Interim CFO Joseph Clay reported his initial beneficial ownership on a Form 3. He shows 1,238,684 shares of Class A common stock held directly, including 912,860 shares underlying the remaining unvested portion of restricted stock unit awards granted on February 16, 2024, October 15, 2024 and December 19, 2025.
Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, had 6,197 shares of Class A Common Stock withheld on April 3, 2026 to cover tax obligations. The withholding related to the vesting of 6.25% of restricted stock units granted on January 3, 2023.
After this tax-withholding disposition, Reynoso directly holds 2,869,922 shares of Class A Common Stock. The remaining RSUs from the 2023 grant will vest in equal quarterly installments through January 3, 2027, subject to Reynoso’s continued service on each vesting date.
Priest Brady Patrick reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments insider Brady Patrick Priest, CEO of Clover Care Services, received an award of 191,261 shares of Class A Common Stock in the form of time-based restricted stock units. These RSUs were granted at no cash purchase price as part of his equity compensation.
After this award, Priest directly holds 2,189,845 shares of Class A Common Stock. Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026, and the remaining units will vest in twelve equal quarterly installments, becoming fully vested on April 1, 2030, assuming his continued service.
Reynoso Jamie L. reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments reported that Jamie L. Reynoso, CEO of Medicare Advantage, received a grant of 159,384 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost per share as equity compensation.
According to the grant terms, 25% of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will vest in twelve equal quarterly installments starting three months after that first anniversary, so that all RSUs are fully vested by April 1, 2030, subject to continued service. Following this award, Reynoso directly holds 2,876,119 shares of Class A common stock.
Clover Health Investments Chief Executive Officer Andrew Toy reported equity compensation changes involving Class A Common Stock. He received a grant of 956,307 shares underlying time-based restricted stock units, with 25% vesting on the first anniversary of April 1, 2026 and the remainder vesting in 12 equal quarterly installments until April 1, 2030, subject to continued service. On the same date, 309,558 shares were automatically withheld at $1.76 per share to cover tax obligations from the vesting of earlier RSUs granted January 1, 2023. After these transactions, he directly holds 10,069,770 shares of Class A Common Stock.
Wai Conrad reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments reported that executive Wai Conrad, CEO of Counterpart Health, received a grant of 267,766 shares of Class A common stock in the form of time-based restricted stock units. The award was granted at $0.00 per share, reflecting a compensation grant rather than a market purchase.
According to the vesting schedule, 25% of these RSUs will vest on the first anniversary of April 1, 2026, with the remaining units vesting in twelve equal quarterly installments beginning three months after that first anniversary, so that all RSUs are fully vested on April 1, 2030, subject to Mr. Conrad’s continued service. Following this grant, he holds 1,193,377 shares directly, and a family trust, for which he is a co-trustee, holds 1,610,482 shares indirectly.
Soares Karen reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments Chief Legal Officer Karen Soares received a grant of 382,522 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost and increase her direct ownership to 1,582,583 shares after the grant.
Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will then vest in twelve equal quarterly installments beginning three months after that first anniversary, with all RSUs fully vested on April 1, 2030, assuming she continues in service through each vesting date.